Oct 29, 2026 · 19 min
GLP-1 microdosing outruns the evidence
People are microdosing GLP-1s for weight loss. Is it safe?
Lower doses and compounded formulations may widen access, but their effectiveness, quality, and risks remain poorly studied.
- 1Microdosing means using less than the lowest FDA-approved dose, but no clinical consensus defines the practice precisely.
- 2Compounding can address legitimate patient needs, yet added ingredients, cycling, and inconsistent oversight make self-directed regimens difficult to assess.
- 3People outside studied obesity or diabetes criteria may face uncertain benefits and side effects, making independent medical follow-up essential.
Don't miss
Joey Mattingly explains why a compounded semaglutide regimen that includes B12 and cycling may feel beneficial while remaining inadequately studied.
The brief
GLP-1 microdosing has become a consumer trend, but the term itself lacks a clinical consensus: it generally means taking less than the lowest FDA-approved dose.
Jorge Moreno and Joey Mattingly explain why compounded drugs can be legitimate, especially for allergies or swallowing difficulties, while lower cost and access drive demand.
The central tension is between genuine individual benefits and missing evidence: added B12, cycling on and off, and lower doses have not been adequately studied together.
The episode widens the concern to people outside approved treatment criteria, whose likely benefits and side effects are less understood than those in clinical studies.
The clearest guidance is practical rather than promotional: avoid self-experimentation, disclose compounded products, and maintain follow-up with an independent regular provider.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.